Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 1Oropharyngeal Neoplasms 1

Interventions

Cisplatin 32Radiotherapy, Intensity-Modulated 17Radiotherapy 17Carboplatin 14Radiation 11Magnetic Resonance Spectroscopy 10Cetuximab 8Specimen Handling 7Platinum 7Paclitaxel 71,2-diaminocyclohexaneplatinum II citrate 7Docetaxel 6Chemoradiotherapy 6Surgical Procedures, Operative 5pembrolizumab 4Nivolumab 4Celecoxib 4cemiplimab 3Taxes 3Surveys and Questionnaires 3Fluorouracil 3Drug Therapy 3toripalimab 2durvalumab 2aldesleukin 2X-Rays 2Standard of Care 2Restraint, Physical 2Observation 2Neck Dissection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oropharyngeal Neoplasms × Vaccines, DNA × Clear all
NCT05799144 2025-10-22

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
54 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡